Key Takeaways AbbVie is advancing Rinvoq expansions, tavapadon and PVEK toward multiple potential product launches.Rinvoq label expansions across five indications could add roughly $2B to peak-year sales.Tavapadon and PVEK are under FDA review as AbbVie expands its pipeline via acquisitions.AbbVie (ABBV) has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology programs and innovat ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisi ...

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the State Street Health Care Select Sector SPDR ETF ETF (XLV) , a passively managed exchange traded fund launched on December 16, 1998.While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.Investor-friendly, sector ETFs provide many options to gain low ris ...

创新奖项将遴选出具有潜力的早期生物技术企业，并为入选企业提供价值50万元的创新支持服务包，包 括飞镖加速器的高标准实验室和办公空间、驻场研发团队支持以及投融资与产业路演对接，以及艾尔建 美学在研发、生产、质量与合规等方面的专业建议。 艾尔建美学副总裁、中国总经理丘汉华表示："我们不仅关注技术突破，更注重与本土化服务体系的适 配。'艾伯维中国创新奖'正是我们践行这一理念的平台——通过资源、专业与产业对接的支持，与中国 创新伙伴深度连接，共创可持续、可复制的中国创新模式。" 据介绍，在未来的发展中，艾尔建美学将持续秉持开放合作的态度，坚持全球统一的质量与科学标准， 支持本土高质量创新项目的培育与发展，为中国医美行业的高质量、可持续发展贡献长期力量。 本报讯(记者金婉霞)12月15日，艾伯维旗下全球医学美容领导企业艾尔建美学在上海举办"中国创新合 作日"，活动汇聚了来自医美产业界、投资界及上游创新领域的先锋力量，围绕中国医美创新趋势、研 发管线进展、商业化合作与产业投资等议题展开了深度交流。会上，艾尔建美学副总裁、亚太及中东非 洲地区总裁王炜表示："中国在全球美学产业的创新版图上，正发挥着前所未有的驱动作用。我们希 ...

Singapore investors often focus on local dividend plays like REITs and bank stocks, and with good reason. However, limiting your portfolio to a single market can constrain growth and expose you to localised risk. For those seeking global diversification and exposure to multi-national growth, here are three US dividend stocks that can add global resilience to your portfolio.AbbVie Inc. (NYSE: ABBV) – Diversified biopharmaceutical firm AbbVie is a global diversified biopharmaceutical company with a portfolio ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

These habitual market beaters can pull it off again.After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to predict those things.No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading into the new year. Let's consider three that are among my favorites to buy: AbbVie (ABBV 0.29%), Eli Lilly (LLY +1.80%), and Intuitive Surgical (ISRG 0.88%). 1. A reliable dividend payerOn ...

Building wealth through dividends requires more than chasing high yields. The path to "getting rich†combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. ...

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

行业概述 - 尽管今年整体股市表现良好，但部分行业板块表现落后于市场，其当前估值水平显得具有吸引力，医疗保健行业便是其中之一 [1] 艾伯维公司分析 - 艾伯维在2025年股价表现已超越市场，且展望2026年，其股票具有吸引力 [2] - 公司虽在2023年失去了史上最畅销药物修美乐的专利独占权，但已迅速恢复营收增长，产品线更加多元化，对单一药物的销售依赖降低 [4][5] - 公司目前整体更健康、风险更低，至少在2030年前无需面对任何主要产品的专利悬崖，这为其未来规划提供了充足时间 [6] - 公司正通过推进关键产品研发管线、达成重要许可协议及收购来加强业务，战略举措积极 [6] - 公司目标之一是更深入地向其他治疗领域多元化发展，包括肿瘤学，其管线中有多个值得关注的候选药物，如用于治疗转移性前列腺癌的ABBV-969和针对肺癌及头颈癌等的ABBV-514 [7] - 公司通过与丹麦Gubra A/S达成许可协议，获得一款在研减肥药GUB014295，从而进入了快速增长的减肥药市场 [8] - 在未来五年内，公司有望在研发管线和监管审批方面取得重大进展，同时持续产生稳定的收入和收益 [8] - 公司是市场上优质的股息股之一，属于“股息之王”，即已连续至少50年每年增加股息，其长期记录彰显了业务的韧性 [10] 默克公司分析 - 默克公司股价在2025年迄今为负收益，但展望2026年，其股票具有吸引力 [2]